First Western Ship Transits Strait of Hormuz Since Iran War Began 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Apple Turns 50: From Garage Startup to AI Crossroads 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SAN FRANCISCO, Oct. 10, 2016 -- Hagens Berman Sobol Shapiro LLP is continuing its investigation of possible securities law violations by Theranos, Inc. and its management.
If you are an investor in Theranos financing rounds and suspect you have lost money, contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/Theranos
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
Our initial investigation indicates that Theranos may have made significant misrepresentations about the state of the Company’s technology and operations when it solicited investments.
On October 6, 2016, the Wall Street Journal reported Theranos would shut down its blood-testing facilities and dismiss more than 40% of its employees after regulators banned Theranos CEO Elizabeth Holmes from owning or operating a lab for two years.
“We’re probing Theranos’s relationships with investors, the representations made to them, and this apparently self-interested shift in business strategy,” said Hagens Berman partner Reed Kathrein. ”Sources indicate that Theranos sold stock in a Series C round to investor in 2014 and 2015. Normally, by the time of a Series C round, the technology or product is proven and the funds are used to expand the products’ presence in the market.”
Whistleblowers: Persons with non-public information regarding Theranos should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the SEC whistleblower program, whistleblowers who provide original information may receive rewards up to 30 percent of any successful recovery made by the SEC. For more information concerning your whistleblower options, call Reed Kathrein at (510) 725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
